Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA's Biosimilars Chief Leah Christl Plans Departure

Executive Summary

A departure date has yet to be determined for the associate director of therapeutic biologics, who helped negotiate and implement the biosimilar user fee program.
Advertisement

Related Content

US FDA Taps Abernethy As Principal Deputy Commissioner; Health IT Exec Brings “Real-World” Expertise
Celltrion’s Rituximab Biosimilar Has Easy US FDA Panel Ride Despite Questions About Narrow Label
Suffix Smackdown: Gottlieb Calls Issue 'Red Herring' For Biosimilars
US FDA's Biosimilar Advisory Committee Policy Evolves
With Biosimilar Statistical Guidance Withdrawn, Expect Sponsor-Specific Advice, FDA's Christl Says
Should A Biosimilar Sponsor Do The 'Patent Dance?' It Depends On Many Things
Best Of Biosimilar Agreement: FDA, Industry Tout Written Response, Pre-Submission Meeting
Jenkins’ Exit Interview: He’ll Miss Insider Status Upon FDA Departure
Biosimilar Advisory Committee Reviews: Necessity Or Nuisance?
Two Out Of Three Ain't Bad: Biosimilar User Fee Talks Completed

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS124539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel